2024
Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.
Aung T, Zhang C, Espinoza G, Leung L, Moon J, Horst B, Ferringer T, Nastiuk K, Rimm D, Saenger Y. Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials. Journal Of Clinical Oncology 2024, 42: 9567-9567. DOI: 10.1200/jco.2024.42.16_suppl.9567.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesRecurrence free survivalAmerican Joint Committee on CancerFree survivalInfiltrating lymphocytesRetrospective cohortClinical trialsQuantify tumor-infiltrating lymphocytesStage II-III melanomaTumor-infiltrating lymphocytes groupDiagnostic slidesIIb-IIIaRoswell Park Comprehensive Cancer CenterEarly-stage melanoma patientsCox modelStage IIB-IIICAdjuvant clinical trialsKaplan-Meier curvesMultivariate Cox modelUnivariate Cox modelCox proportional hazards modelsClinical pathological featuresGeisinger Medical CenterProportional hazards modelClinical trial design
2022
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine 2022, 82: 104143. PMID: 35810563, PMCID: PMC9272337, DOI: 10.1016/j.ebiom.2022.104143.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesMelanoma patientsPrognostic valuePrognostic markerPrimary melanoma patientsRobust prognostic markerStage II patientsSpecific molecular subtypesTIL phenotypeAdjuvant therapyOverall survivalSurgical treatmentTIL scoreII patientsSurvival outcomesLung cancerClinical trialsPrimary melanomaClinical impactT cellsMolecular subtypesHigh riskIndependent cohortLower riskEosin staining
2021
Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer
MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers 2021, 13: 5501. PMID: 34771664, PMCID: PMC8583434, DOI: 10.3390/cancers13215501.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesPancreatic ductal adenocarcinomaCancer-associated fibroblastsImmune checkpoint blockadePancreatic cancerCheckpoint blockadePDAC patientsTumor microenvironmentQuantitative immunofluorescenceExpression levelsProgression-free survivalLarge retrospective cohortMajority of patientsPotential prognostic valueLow tumor immunogenicityPotential clinical utilityDesmoplastic tumor microenvironmentImmunoinhibitory proteinOverall survivalRetrospective cohortIndependent predictorsImmunotherapy drugsPrognostic significancePrognostic valueTumor expression